Citations

Showing 10 of 108104 citations.

Improving Turnaround Time in a Hospital-based CT Division with the Kaizen Method
Flug, Jonathan A. , Stellmaker, Jessica A. , Tollefson, Chris , Comstock, Elaine M. , Buelna, Efren, Truman, Brooke, Ponce, Lisa , Milosek, Amy , McCabe, J.F., Jokerst, Clinton, Tollefson, Chris D , McCabe, John, Jokerst, Clinton E , Flug, Jonathan A , McCabe, John

Mayo Clinic

RadioGraphics | May 27, 2022 | Volume: 42 | Issue: 4 | Pages: E125-E131

10.1148/rg.210128 | PMID 35622490 Get It

Drug Interactions Affecting Oral Anticoagulant Use
Mar, Philip L. , Gopinathannair, Rakesh , Gengler, Brooke , Chung, Mina K. , Perez, Arturo, Dukes, Jonathan W., Ezekowitz, Michael D. , Lakkireddy, Dhanunjaya , Miletello, Mike, Reiffel, James A. , Gengler, Brooke E , Lip, Gregory Y H , Miletello, Mike , Noseworthy, Peter A , Reiffel, James A , Tisdale, James E , Olshansky, Brian , Gopinathannair, Rakesh , Noseworthy, Peter A. , Olshansky, Brian

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | May 27, 2022 | Volume: 15 | Issue: 6 | Pages: No page available

10.1161/circep.121.007956 | PMID 35622425 Get It

Oral anticoagulants (OACs) are medications commonly used in patients with atrial fibrillation and other cardiovascular conditions. Both warfarin and direct oral anticoagulants are susceptible to drug-drug interactions (DDIs). DDIs are an important cause of adverse drug reactions and exact a large toll on the health care system. DDI for warfarin mainly involve moderate to strong inhibitors/inducers of cytochrome P450 (CYP) 2C9, which is responsible for the elimination of the more potent S-isomer of warfarin. However, inhibitor/inducers of CYP3A4 and CYP1A2 may also cause DDI with warfarin. Recognition of these precipitating agents along with increased frequency of monitoring when these agents are initiated or discontinued will minimize the impact of warfarin DDI. Direct oral anticoagulants are mainly affected by medications strongly affecting the permeability glycoprotein (P-gp), and to a lesser extent, strong CYP3A4 inhibitors/inducers. Dabigatran and edoxaban are affected by P-gp modulation. Strong inducers of CYP3A4 or P-gp should be avoided in all patients taking direct oral anticoagulant unless previously proven to be otherwise safe. Simultaneous strong CYP3A4 and P-gp inhibitors should be avoided in patients taking apixaban and rivaroxaban. Concomitant antiplatelet/anticoagulant use confers additive risk for bleeding, but their combination is unavoidable in many cases. Minimizing duration of concomitant anticoagulant/antiplatelet therapy as indicated by evidence-based clinical guidelines is the best way to reduce the risk of bleeding.
The role of cytokines and their antagonists in the treatment of COVID‐19 patients
Afshar, Zeinab Mohseni , Barary, Mohammad , Pirzaman, Ali Tavakoli , Hosseinzadeh, Rezvan , Alijanpour, Amirmasoud , Allahgholipour, Amirreza , Miri, Seyed Rouhollah , Sio, Terence T. , Sullman, Mark J. M. , Carson‐Chahhoud, Kristin , Ebrahimpour, Soheil , Mohseni Afshar, Zeinab , Babazadeh, Arefeh , Tavakoli Pirzaman, Ali , Hosseinzadeh, Rezvan , Alijanpour, Amirmasoud , Allahgholipour, Amirreza , Miri, Seyed Rouhollah , Sio, Terence T , Sullman, Mark J M , Carson-Chahhoud, Kristin , Ebrahimpour, Soheil , Barary, Mohammad

Mayo Clinic

Reviews in Medical Virology | May 27, 2022 | Volume: 33 | Issue: 1 | Pages: No page available

10.1002/rmv.2372 | PMID 35621229 Get It

AbstractThe coronavirus disease 2019 (COVID‐19) has various presentations, of which immune dysregulation or the so‐called cytokine storm syndrome (COVID‐CSS) is prominent. Even though cytokines are vital regulators of body immunoinflammatory responses, their exaggerated release can be harmful. This hyperinflammatory response is more commonly observed during severe COVID‐19 infections, caused by the excessive release of pro‐inflammatory cytokines, such as interleukin‐1 (IL‐1), IL‐6, IL‐8, tumour necrosis factor, granulocyte‐macrophage colony‐stimulating factor, and interferon‐gamma, making their blockers and antagonists of great interest as therapeutic options in this condition. Thus, the pathophysiology of excessive cytokine secretion is outlined, and their most important blockers and antagonists are discussed, mainly focussing on tocilizumab, an interleukin‐6 receptor blocker approved to treat severe COVID‐19 infections.
Generalizability of the EAST‐AFNET 4 Trial: Assessing Outcomes of Early Rhythm‐Control Therapy in Patients With Atrial Fibrillation
Dickow, Jannis , Kirchhof, Paulus , Houten, Holly K. Van , Sangaralingham, Lindsey R. , Dinshaw, Leon , Friedman, Paul A. , Packer, Douglas L. , Noseworthy, Peter A. , Yao, Xiaoxi , Van Houten, Holly K , Dinshaw, Leon H W , Noseworthy, Peter A , Kirchhof, Paulus , Yao, Xiaoxi

Mayo Clinic

Journal of the American Heart Association | May 27, 2022 | Volume: 11 | Issue: 11 | Pages: No page available

10.1161/jaha.121.024214 | PMID 35621202 Get It

Background EAST‐AFNET 4 (Early Treatment of Atrial Fibrillation for Stroke Prevention Trial) demonstrated clinical benefit of early rhythm‐control therapy (ERC) in patients with new‐onset atrial fibrillation (AF) and concomitant cardiovascular conditions compared with current guideline‐based practice. This study aimed to evaluate the generalizability of EAST‐AFNET 4 in routine practice. Methods and Results Using a US administrative database, we identified 109 739 patients with newly diagnosed AF during the enrollment period of EAST‐AFNET 4. Patients were classified as either receiving ERC, using AF ablation or antiarrhythmic drug therapy, within the first year after AF diagnosis (n=27 106) or not receiving ERC (control group, n=82 633). After propensity score overlap weighting, Cox proportional hazards regression was used to compare groups for the primary composite outcome of all‐cause mortality, stroke, or hospitalization with the diagnoses heart failure or myocardial infarction. Most patients (79 948 of 109 739; 72.9%) met the inclusion criteria for EAST‐AFNET 4. ERC was associated with a reduced risk for the primary composite outcome (hazard ratio [HR], 0.85; 95% CI, 0.75–0.97 [ P =0.02]) with largely consistent results between eligible (HR, 0.89; 95% CI, 0.76–1.04 [ P =0.14]) or ineligible (HR, 0.77; 95% CI, 0.60–0.98 [ P =0.04]) patients for EAST‐AFNET 4 trial inclusion. ERC was associated with lower risk of stroke in the overall cohort and in trial‐eligible patients. Conclusions This analysis replicates the clinical benefit of ERC seen in EAST‐AFNET 4. The results support adoption of ERC as part of the management of recently diagnosed AF in the United States.
The Effect of Glucagon on Protein Catabolism During Insulin Deficiency: Exchange of Amino Acids Across Skeletal Muscle and the Splanchnic Bed
James, Haleigh, Manjunatha, S , Dasari, Surendra , Klaus, Katherine A. , Vella, Adrian , Andrews, James C. , Nair, K. Sreekumaran , Manjunatha, Shankarappa, Lanza, Ian R , Vella, Adrian , Nair, K Sreekumaran , Gonsalves, Wilson I. , Lanza, Ian R.

Mayo Clinic

Diabetes | May 27, 2022 | Volume: 71 | Issue: 8 | Pages: 1636-1648

10.2337/db22-0079 | PMID 35621914 Get It

Transient insulin deprivation with concurrent hyperglucagonemia is a catabolic state that can occur in type 1 diabetes. To evaluate glucagon’s catabolic effect in the setting of its glucogenic effect, we measured the regional exchanges of amino acid metabolites (amino-metabolites) across muscle and splanchnic beds in 16 healthy humans during either somatostatin followed by glucagon or saline infusion alone. Despite a twofold or greater increase in the regional exchange of amino-metabolites by glucagon, whole-body kinetics and concentrations of amino acids (AA) remained stable. Glucagon increased the splanchnic uptake of not only gluconeogenic but also essential (EAA) AA while increasing their release from the muscle bed. Regional tracer-based kinetics and 3-methylhistidine release indicate that EAA release from muscle is likely caused by reduced protein synthesis rather than increased protein degradation. Furthermore, many metabolites known to affect insulin action and metabolism were altered by hyperglucagonemia including increase in branched-chain AA and keto acids of leucine and isoleucine in arterial plasma. Further, an increase in arterial concentrations of α-aminoadipic acid arising from increased conversion from lysine in the splanchnic bed was noted. These results demonstrate that hyperglucagonemia during hypoinsulinemia increases net muscle protein catabolism and substantially increases the exchange of amino metabolites across splanchnic and muscle beds.
Current approach of primary bilateral adrenal hyperplasia
Delivanis, Danae A. , Vassiliadi, Dimitra A. , Tsagarakis, Stylianos

Mayo Clinic

Current Opinion in Endocrinology, Diabetes & Obesity | May 27, 2022 | Volume: 29 | Issue: 3 | Pages: 243-252

10.1097/med.0000000000000725 | PMID 35621176 Get It

Purpose of review To discuss the most recent findings on the pathophysiology, the genetic and molecular causes of primary bilateral adrenal hyperplasia (PBAH). The diagnostic approach of patients with PBAH will also be presented in detail with an emphasis on the emerging diagnostic tools and finally, the treatment of PBAH will be discussed with an emphasis on the newest surgical and medical treatment approaches. Recent findings PBAH is a highly heterogeneous condition mostly detected incidentally on abdominal imaging. Based on the size of the nodules, PBAH is subdivided into primary bilateral macronodular adrenal hyperplasia (PBMAH) and micronodular adrenal hyperplasia. A substantial proportion of patients with PBMAH harbor a germline mutation of the armadillo repeat containing 5 tumor suppression gene and therefore genetic testing is strongly recommended. Measurements of plasma or urinary multisteroid profiles show promising results in that PBMAH has a distinctive plasma steroid fingerprint that can help in diagnosis and subtyping of PBMAH. Finally, although surgery is the mainstay of treatment of patients with PBAH, medical therapy is increasingly emerging as an alternative option. Summary PBAH is a poorly studied and therefore a challenging disease to diagnose and treat. Hopefully with these newest diagnostic and therapeutic tools, a more comprehensive approach will be adopted.
Dynamic Vertebral Artery Compression by Solitary Osteochondroma Presenting With Recurrent Posterior Circulation Strokes
Oushy, Soliman , Savastano, Luis , Brinjikji, Waleed , Klaas, James P. , Clarke, Michelle, Savastano, Luis E , Brinjikji, Waleed , Klaas, James P , Oushy, Soliman H , Clarke, Michelle J.

Mayo Clinic

Stroke | May 27, 2022 | Volume: 53 | Issue: 8 | Pages: No page available

10.1161/strokeaha.122.039124 | PMID 35620990 Get It

Resolution of severe cardiomyopathy after catheter ablation of an anteroseptal accessory pathway: A case report
Baqal, Omar , Ladia, Vatsal, Baqal, Omar J , Masry, Hicham El

Mayo Clinic

No container title available | May 27, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.165363314.43425560/v1 Get It

Background: In patients with non-sustained tachyarrhythmias, left ventricular (LV) systolic dysfunction is uncommon. The role of catheter ablation (CA) in asymptomatic patients with tachyarrhythmia remains unclear. Case presentation: We report a 20-year-old patient without sustained tachyarrhythmia with a left ventricular ejection fraction of 20% who underwent radiofrequency catheter ablation (RFCA) of anteroseptal accessory pathway. She achieved normalization of left ventricular systolic function noted on echocardiography performed at four weeks post-ablation. Conclusions: Our case highlights significant improvement in LV systolic function after catheter ablation of an “asymptomatic” ventricular preexcitation. Current guidelines do not endorse ablating asymptomatic patients, but careful follow up with serial echocardiograms might be warranted. Prophylactic ablation of those patients with clear evidence of LV dyssynchrony or wide left bundle branch pattern and persistent preexcitation is worth further consideration.
A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome
Chohan, Karan , Moustafa, Muhamad Alhaj , Tun, Han W. , Hoppe, Bradford S. , Johnston, Patrick B. , Micallef, Ivana N. , Ansell, Stephen M. , Chohan, Karan L, Moustafa, Muhamad Alhaj , Tun, Han W , Hoppe, Bradford S , Chohan, Karan L , Young, Jason R. , Lester, Scott C. , Rosenthal, Allison , Habermann, Thomas M.

Mayo Clinic

Blood Advances | May 26, 2022 | Volume: 6 | Issue: 14 | Pages: 4241-4250

10.1182/bloodadvances.2022007363 | PMID 35617689 Get It

Abstract Multiple clinical trials have assessed de-escalation strategies from combined modality therapy (CMT) to chemotherapy-alone for the treatment of early-stage classical Hodgkin lymphoma (cHL), confirming similar outcomes. The application of these data to the real-world is limited, however. We conducted a retrospective, multicenter cohort study comparing CMT vs chemotherapy-alone in patients with early-stage cHL (stage IA-IIB) treated between January 2010 and December 2020. Positron emission tomography (PET) scans after chemotherapy cycle 2 (PET2) were independently reviewed by a nuclear radiologist (Deauville score ≥4, positive; ≤3, negative). Patient outcomes were compared by using an intention-to-treat analysis. Among 125 patients (CMT, n = 63; chemotherapy-alone, n = 62) with a median follow-up of 59.8 months (95% CI, 48.6-71.0), no differences in overall survival were observed (5-year overall survival, CMT 98.0% vs chemotherapy-alone 95.1%; log-rank test, P = .38). However, there was reduced progression-free survival (PFS) with chemotherapy-alone among all patients (2-year PFS, CMT 95.1% vs chemotherapy-alone 75.3%; log-rank test, P = .005) and in those with bulky (n = 43; log-rank test, P < .001), unfavorable (n = 81; log-rank test, P = .002), or PET2-positive (n = 15; log-rank test, P = .02) disease. No significant differences in PFS were seen for patients with non-bulky (log-rank test, P = .35), favorable (log-rank test, P = .62), or PET2-negative (log-rank test, P = .19) disease. Based on our real-world experience, CMT seems beneficial for patients with early-stage cHL, especially those with PET2-positive and unfavorable disease. Chemotherapy-alone regimens can lead to comparable outcomes for patients with favorable, non-bulky, or PET2-negative disease. We conclude that although results seen in clinical trials are replicated in certain patient subgroups, other subgroups not fitting trial criteria do poorly when radiotherapy is excluded.
Economic Cost and Sustainability of Oral Therapies in Precision Oncology
Desai, Aakash , Scheckel, Caleb , Soderberg, Leah C. , Jensen, Chelsee , Orme, Jacob J. , Tella, Sri Harsha , Kommalapati, Anuhya , Pritchett, Joshua C. , Khera, Nandita , Mahipal, Amit , Desai, Aakash P , Scheckel, Caleb J , Jensen, Chelsee J , Tella, Sri H, Go, Ronald S , Mahipal, Amit , Kommalapati, Anuhya , Pritchett, Joshua , Soderberg, Leah , Go, Ronald S.

Mayo Clinic

JCO Oncology Practice | May 26, 2022 | Volume: 18 | Issue: 8 | Pages: e1247-e1254

10.1200/op.21.00847 | PMID 35617640 Get It

PURPOSE: Precision oncology promises improved outcomes but the cost-effectiveness and accessibility of targeted therapies is debatable. We report price change patterns from 2015 to 2019 for several oral anticancer medications for common solid tumor malignancies. METHODS: We collected provider utilization and payment data from the public Medicare Part D database and extracted drug price information for commonly prescribed targeted oral anticancer agents for lung, breast, and prostate cancer. We then calculated median Pearson correlation coefficient values for various drugs (containing more than two data points) within each therapeutic class. We also calculated compound annual growth rates (CAGRs) for medication costs within each class and compared them with the consumer price index (CPI). RESULTS: Our study included six epidermal growth factor receptor inhibitors (EGFRi; one generic), five anaplastic lymphoma kinase inhibitors (ALKi), two B-Raf inhibitors (BRAFi), three hormonal agents (one generic), three cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i), two poly-ADP-ribose inhibitors (PARPi), and seven antiandrogen agents (two generic). The median (range) Pearson correlation coefficient values for cost of drugs within each therapeutic class were 0.967 (0.915-0.978) for EGFRi, 0.981 (0.966-0.989) for ALKi, 0.996 for BRAFi, 0.994 (0.992-0.999) for CDK4/6i, 0.855 for PARPi, and 0.442 (–0.522 to 0.962) for antiandrogens. Therapies with two or fewer data points (generic erlotinib, dacomitinib, abiraterone, apalutamide, and darolutamide) were excluded. The median CAGRs in costs over the 5-year period were 4.56% (EGFRi), 6.40% (ALKi), 2.58% (BRAFi), 5.48% (hormonal agents), 5.21% (CDK4/6i), 27.29% (PARPi), and 34.8% (antiandrogens). The CPI over 5 years was 2.26%/year, and the average inflation rate was 1.90%/year. CONCLUSION: The median CAGR in costs for modern oral precision-driven cancer therapeutic classes mostly outpaced CPI and the average inflation. Increase in cost within the same class should be weighed against incremental clinical benefit for the patients to ensure that rising costs do not limit access to targeted therapies.